kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human PLAU / uPA Protein, His tag, 50µg  

Recombinant human PLAU / uPA Protein, His tag, 50µg

Recombinant human PLAU / uPA Protein, Ser 21 - Leu 431, produced in human 293 cells (HEK293), His tag

recombinant, human, protein, Urokinase, PLAU, ATF, UPA

More details


Availability: within 7 days

372,00 €

Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

Recombinant human PLAU / uPA Protein (Human PLAU, His Tag) Ser 21 - Leu 431 (Accession # NP_002649.1) was produced in human 293 cells (HEK293).

Molecular Characterization
Human PLAU, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 47.2 kDa. The protein migrates as 45-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg of the Human PLAU, His Tag by the LAL method.

>95% as determined by SDS-PAGE.

Please refer to product data sheet.

Lyophilized from 0.22 μm filtered solution in 50 mM NaAc, 100 mM NaCl, pH5.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).


(1) Nagai M., et al., 1985, Gene 36:183.
(2) Jacobs P., et al., 1985, DNA 4:139.
(3) Harbeck, N. et al., 2002, Clin. Breast Cancer 3:196.